Hindawi Publishing Corporation
Interdisciplinary Perspectives Infectious Diseases
Volume 2014, Article ID 453186, 7 pages
http://dx.doi.org/10.1155/2014/453186




Review Article
Serine Proteases Malaria Parasite Plasmodium falciparum:
Potential Antimalarial Drug Targets

           Asrar Alam
           Department Biological Sciences, Tata Institute Fundamental Research, Homi Bhabha Road, Colaba, Mumbai-400005, India

           Correspondence addressed Asrar Alam; asraralam22@yahoo 
           Received 25 October 2013; Revised 2 January 2014; Accepted 7 January 2014; Published 11 March 2014

           Academic Editor: Mary E. Marquart

           Copyright Â© 2014 Asrar Alam. open access article distributed Creative Commons Attribution License,            permits unrestricted use, distribution, reproduction medium, provided original work properly cited.

           Malaria major global parasitic disease cause enormous mortality morbidity. Widespread drug resistance            currently available antimalarials warrants identification novel drug targets development new drugs. Malarial proteases
           group molecules serve potential drug targets essentiality parasite life cycle stages feasibility
           designing specific inhibitors  Proteases belonging various mechanistic classes P. falciparum,            serine proteases particular involvement parasite-specific processes egress invasion. P.
           falciparum, number serine proteases belonging chymotrypsin, subtilisin, rhomboid clans  review focuses
           potential P. falciparum serine proteases antimalarial drug targets.




1. Global Malaria Burden Need                                        plant effective antimalarials. Quinoline
   Development Novel Antimalarials                                        compound chloroquine widely used drug
                                                                             recently. Resistance chloroquine started Africa Malaria caused protozoan parasite Plasmodium major                   1980s, causing tremendous resurgence malaria burden
global parasitic disease [1]. Malaria humans caused                 [3, 4]. Chloroquine resistance prompted countries Plasmodium species,  P. falciparum, P. vivax, P.                 adopt sulfadoxine-pyrimethamine (SP) line anti-
ovale, P. malariae, P. knowlesi.  P. falciparum              malarial resistant P. falciparum populations selected causative agent severe malaria major cause                 quickly Africa, Southeast Asia, South America. malaria-related fatality.                                                    abandoned 5 years use Southeast Asia [5, 6].
    According World Malaria Report 2013,                    widespread resistance available antimalarials, estimated 207 million clinical cases malaria 2012                   artemisinin-based combination therapies (ACTs) intro- estimated 627,000 deaths, 90  deaths                    duced Asia, Africa, South America. artemisinins
occurring sub-Saharan Africa. International efforts                    potent rapidly acting antimalarials derived control malaria resulted significant reduction                    Chinese sweet wormwood plant, Artemisia annua [7, 8].
malaria-related deaths. 2000 2012, malaria-                      short duration action, artemisinins related deaths reduced 29  globally 31                         administered  results recrudescent para- African Region [2]. Methods used prevent                          sitemia [9];  administered ACTs spread disease protect individuals areas               days combinations longer-acting antimalar-
malaria endemic include therapeutic prophylactic                      ials forms artemether-lumefantrine, amodiaquine-
drugs, mosquito eradication, prevention mosquito                      artesunate, mefloquine-artesunate [10]. Despite effec-
bites using insecticide-treated nets (ITNs), indoor residual              tiveness ACTs, use artemisinin monotherapy resulted
spray, larval control [2].                                               emergence drug-resistant P. falciparum parasites     Early antimalarial agents isolated natural prod-               Cambodia-Thailand border region [11, 12]. According ucts. Bark cinchona tree extracts wormwood                  till drug resistance reported 2                                                                            Interdisciplinary Perspectives Infectious Diseases

Plasmodium species, P. falciparum, P. vivax, P. malariae         relatively large metabolically active trophozoite
[13].                                                                stage parasite, transforms multinucleated
    Currently treatment malaria effected mainly        schizont. Inhibitor-based studies shown cysteine, administration chloroquine, SP, ACTs. Prophy-             aspartic, metallo, serine protease activities crucial lactic drugs include chloroquine, primaquine, mefloquine,            completion cycle [24]. previous studies doxycycline, malarone (atovaquone proguanil) [14].           implicated functional role serine proteases egress Despite availability antimalarials treatment         invasion blood stages [25â€“27]. prophylaxis, spread resistance paucity antimalarials warrants need identification new
drug targets development novel drugs.                         3. P. falciparum Serine Proteases
                                                                     Serine proteases widely dispersed organisms                                                                      evolution diverse functions. 2. Proteases Antimalarial Drug Targets                            grouped thirteen clans [28]. Chymotrypsin/trypsin-like
Proteases constitute ubiquitous highly abundant group          subtilisin-like serine proteases major clans of catalytic regulatory molecules having widespread              serine proteases, highly similar arrangement roles living systems. primarily involved protein      catalytic triad Asp,  Ser residues radically differ-
turnover constituent amino acids generate            ent protein scaffolds,  ð?›½/ð?›½ chymotrypsin ð?›¼/ð?›½
building blocks new proteins digestion dietary            subtilisin [29]. number serine proteases belonging
proteins higher organisms.  protein activation            chymotrypsin, subtilisin, rhomboid protease clans limited proteolysis common means regulation            P. falciparum genome. list P. falciparum physiological processes [15]. Proteases constitute          serine proteases orthologs putative
major virulence factors various parasitic diseases        functions presented Table S1 (Supplementary Materials
schistosomiasis, malaria, leishmaniasis, Chagas disease,         available online http://dx.doi.org/10.1155/2014/453186).
African sleeping sickness. characterized examples          pro-teases expressed temporally regulated roles proteases parasite pathogenesis include           manner asexual sexual stages parasite life involvement invasion host cells, degradation         cycle [30â€“32]. Table S2 presents microarray mass hemoglobin blood proteins, immune evasion,              spectrometry based expression profiles P. falciparum activation inflammation [16]. context,       serine proteases. proteases known crucial pathogenic organisms survival         essential parasite development erythrocytic diseases cause. potential drug targets      exoerythrocytic stages suggesting potential targets
underscored feasibility designing specific inhibitors      therapeutic intervention. 
     Proteases recognize optimum peptide sequence             3.1. P. falciparum Chymotrypsin-Like Proteases. genes
catalyze cleavage active site. Selective inhibitors       encoding serine proteases chymotrypsin-like clan
targeting active sites developed. active      (PlasmoDB IDs: PF3D7 0807700 PF3D7 0812200) sites, exosites allosteric sites participate substrate   identified P. falciparum genome. PF3D7 0807700 homol-
recognition.  selective inhibitors targeting sites       ogous DegP heat shock protein family [33]. DegP developed [17].                                          acts chaperone low temperature protease      Protease inhibitors successfully used drugs        elevated temperature, role extracellular process related human immunodeficiency virus (HIV) [18]                  invasion unlikely. second putative chymotrypsin-
hepatitis C virus (HCV) [19] treatment hypertension        like serine protease PF3D7 0812200 possesses PDZ2 domain
[20] coagulopathies [21]. active sites proteases          trypsin domain. domain prokary- successfully targeted viruses HIV              otic, viral, eukaryotic signaling proteins having GTPase
HCV angiotensin-converting enzyme hypertension                activity [34], known anchor transmembrane proteins
[22, 23]. Targeting active site feasible       cytoskeleton assembly signaling complexes. homology host enzymes. example,              protease unlikely directly involved invasion.
cancers, development protease inhibitor-based drugs challenging difficulty selectively targeting active sites. cases, allosteric sites           3.2. P. falciparum Subtilisin-Like Proteases. genes
targeted achieve goals [17]. Malaria parasite     encoding proteases major clan, subtilisin-
important member parasites phylum Apicomplexa,             like proteases subtilases (clan SB) [35], P. invade host cell reside intracellular niche         falciparum genome known PfSUB1, 2, 3. protected host defenses provides rich             highly expressed late asexual blood stages [31]. source nutrient. Asexual erythrocytic life cycle malaria        PfSUB1 2 extensively characterized
parasite responsible clinical symptoms malaria.        implicated egress invasion asexual blood starts invasion erythrocytes merozoites        stage life cycle parasite [26, 27, 36]. PfSUB3 released liver. intraerythrocytic parasite feeds         characterized member preliminary reports host hemoglobin develops small ring stage form              confirmed vitro serine protease activity PfSUB3
Interdisciplinary Perspectives Infectious Diseases                                                                            3
 identified multifunctional parasite protein, pro-        inhibitor, defective merozoites released [51].
filin, interacting partner [37, 38].                         DPAP3 caused maturation PfSUB1 [27]. mature
                                                                    PfSUB1 caused processing parasitophorous vacuolar
                                                                    proteins SERA5 [27] SERA6 [52], implicated
3.2.1. P. falciparum Subtilisin-Like Protease 1 (PfSUB1).           merozoite egress.
PfSUB1 (PlasmoDB ID: PF3D7 050700 MEROPS iden-                       Merozoite surface protein 1 (MSP1) complex large
tification number S08.012) identified member        glycosylphosphatidylinositol (GPI)-anchored protein com-
P. falciparum subtilases. primary structure PfSUB1           plex, comprised MSP1 associated partner
classifies small group bacterial-like eukaryotic         proteins MSP6 MSP7. erythrocyte invasion,
subtilases [29, 35]. PfSUB1 undergoes major intracellular       initial low affinity interaction host cell takes
processing steps maturation. takes place       place complex [53â€“55]. Proteolytic processing
inside lumen endoplasmic reticulum converts          (primary processing) complex necessary initial
earliest detectable 82 kDa form 54 kDa form (p54)            low affinity interaction host parasite [39]. second, brefeldin sensitive processing step,     erythrocyte invasion. later stage, processing
conversion p54 intracellular 47 kDa terminal processing       complex required movement merozoite
product (p47); p54 p47 contain predicted               inside host cell (secondary processing) [36]. PfSUB1
catalytic domain [40].                                              carries primary processing MSP1 complex      Expression codon-optimized PfSUB1 gene                   parasitophorous vacuole spatiotemporally regulated
recombinant baculovirus-infected insect cells resulted       manner [56].  PfSUB1 cleaves number mero-
secretion processed form (p54) [39]. N-terminal radio-       zoite parasitophorous vacuolar proteins [57]. sequencing vitro translated protein showed            blood stages, SUB1 essential liver developmental
cleavage Asp219 Asn220 sequence Leu-         stages. Conditional knockout Plasmodium berghei SUB1
Val-Ser-Ala-Asp-Asn-Ile-Asp-Ile-Ser. highly restricted         (PbSUB1) revealed SUB1, essential early
substrate specificity PfSUB1 suggestive             liver stage development, essential development specialized nondegradative biological function           liver stage schizonts production merozoites [58]. 
parasite [39, 41]. substantial fraction insect cell-secreted   ditional mutagenesis studies showed PbSUB1-deficient
p54 bound 31 kDa propeptide (rp31),          merozoites unable egress hepatocytes [59]. highly selective, high-affinity inhibitor protease          Recently attempts identify PfSUB1 dissociation constant nanomolar range (Kiâˆ¼12.5 nM)          inhibitors. Maslinic acid (MA), low toxic natural penta-
[39]. Truncation 11 residues C-terminal rp31         cyclic triterpene, inhibit P. falciparum blood
substantially reduced inhibition PfSUB1 activity [42].     stage transition ring schizont stage multitargeted
subtilase propeptides specific inhibitors cognate      mechanism. MA inhibit proteolytic pro-
proteases [43â€“47], inhibitory peptides proregion       cessing MSP1 complex, probably targeting PfSUB1 facilitate designing specific inhibitors protease.   [60]. Characterization PfSUB1 orthologs P. vivax, P.
     Plasmodium proteins possess structural insertions         knowlesi, P. berghei revealed homologs genera [48, 49].             number unusual features SUB1 substrate binding insertions provide targets highly selective           cleft, cleavage sites parasite substrates proteases
therapies P. falciparum. Comparison PfSUB1               conserved. peptidyl alpha-ketoamide inhibitors primary structure orthologs related bacterial          PfSUB1 inhibited orthologs suggesting small
subtilisins revealed presence high low              molecule inhibitors developed protease
complexity insertions predicted form surface            [61]. molecular dynamics simulation study binding strand loop structures. Site-directed mutagenesis, deletion      known PfSUB1 substrate peptides based prodomain loop insertions, strategic replacements             revealed prime nonprime sides scissile
revealed majority loop insertions critical      bond make major contribution binding free energy. activity protease [50].                              comprises peptide residues P4 P2ó¸€  making region
     PfSUB1 gene refractory deletion             potential designing peptidomimetic inhibitors blood stages. stored apical organelles, distinct       PfSUB1 [62]. Given essentiality parasite blood involved erythrocyte invasion termed           liver stages, proteolytic activity multiple parasite
â€œexonemesâ€? [26]. final stage schizont matu-           proteins, role egress invasion, PfSUB1 qualifies ration, discharged parasitophorous vacuole          attractive antimalarial drug target.
(PV) triggered series proteolytic events resulting merozoite egress [27]. attempt identify mediators egress, Arastu-Kapur et al. tested effect library    3.2.2. P. falciparum Subtilisin-Like Protease 2. P. falciparum
1,200 focused serine cysteine protease inhibitors blood      subtilisin-like protease 2 (PfSUB2) (PlasmoDB ID: 248
stage malaria parasite growth. Using hits library          PF3D7 1136900 MEROPS identification number:
screening, identified PfSUB1 dipeptidyl aminopep-          S08.013) type 249 transmembrane protein ex-
tidase 3 (DPAP3) primary regulators egress.               pressed late asexual blood stages. Attempts disrupt P.
Inhibition PfSUB1 DPAP3 caused block schizont           berghei ortholog PfSUB2 (PbSUB2) double-crossover
rupture [27] relatively lower concentration            integration unsuccessful, suggesting potential
4                                                                         Interdisciplinary Perspectives Infectious Diseases
 PfSUB2 drug target [63]. secreted merozoite    smaller sizes, hydrolyzed increasing concen-
apical organelles â€œmicronemesâ€? plays critical role       tration PfSUB3 [38]. clear proteolytic
merozoite invasion red blood cells (RBCs) [36].                activity causes maturation PfPRF degradation     PfSUB2 causes shedding merozoite adhesins MSP1             physiological conditions. Given serine protease activity apical membrane antigen 1 (AMA1) juxtamembrane           PfSUB3 multiple physiological functions PfPRF,
site invasion [64]. Cleavage MSP1 PfSUB2              motility, egress, induction, proinflammatory
takes place distal epidermal growth factor- (EGF-)          cytokines, role related processes needs explored
like domain C-terminal called MSP119 [53]. MSP119          [38].
remains bound merozoite surface MSP1, enters host cell. Cleavage AMA1 takes places 29 residues away transmem-             3.3. P. falciparum Rhomboid Proteases. Rhomboid proteins
brane domain, releasing bulk ectodomain.            intramembranous serine proteases catalytic way, juxtamembrane â€œstubâ€? cognate         triad embedded membrane bilayer, surrounded
transmembrane domain (TMD) cytoplasmic domain                 hydrophilic cavity formed protein ring [70]. enters host cell [65]. Shedding proteins        rhomboid protease genes P. falciparum genome. essential productive invasion [65â€“67]. PfSUB2        P. falciparum rhomboids largely uncharacterized till date.
causes shedding MSP1 AMA1 mov-                  characterized members P. falciparum rhomboids
ing junction erythrocyte invasion, termed         PfROM1 PfPROM4. PfROM1 localizes thread-
â€œmerozoite surface sheddaseâ€? (MESH). protein             like apical organelle blood stage merozoites termed expressed recombinant proteolytically active          â€œmononemeâ€? [71] surface sporozoites form shows MESH activity purified mero-                salivary gland invasion [72]. Plasmodium yoelii ROM1 defi-
zoites. translocates anterior posterior        cient parasites attenuated erythrocytic hep-
end merozoite actin-dependent movement               atic stages defective parasitophorous vacuole (PV) merozoite enters host erythrocyte [36].           development [73]. PfROM1 PfROM4 helped merozoite
                                                                  invasion catalyzing intramembrane cleavage      Like PfSUB1, PfSUB2 undergoes proteolytic process-      merozoite adhesin AMA1 [65, 74] erythrocyte binding
ings parasite, probable maturation          antigen 175 (EBA-175), respectively [75]. PfROM1 4
events. open reading frame encoding PfSUB2         able cleave variety adhesins involved host
vitro translated, revealed 154.8 kDa primary       parasite interaction transmembrane domains [74].
translated product (SUB2p) underwent rapid conversion          initial reports proteases suggestive
74 kDa intermediate species (SUB2I ) quantita-          importance parasite development, tively converted terminal 72 kDa species (SUB2T ) [68].        remain extensively characterized assessed prodomain PfSUB2 selective          therapeutic value.
inhibitor â€œsheddaseâ€? activity [36]. Nuclear magnetic
resonance (NMR) structure PfSUB2 prodomain identified likely catalytic domain-binding interface region  exploited design peptidomimetic inhibitor     4. Conclusion protease [69]. Essentiality protease parasite
                                                                  P. falciparum serine proteases particular survival, involvement RBC invasion, initial 
                                                                  potential antimalarial drug targets role ings suggesting feasibility designing inhibitors                                                                   processes egress invasion erythrocytic preery- protease make PfSUB2 promising drug target                                                                   throcytic stages, critical checkpoints parasite
malaria.
                                                                  development blocked. Involvement parasite serine
                                                                  proteases processing parasite molecules involved 3.2.3. P. falciparum Subtilisin-Like Protease 3. P. falciparum    molecular interactions parasite invasion cleavage
subtilisin-like protease 3 (PfSUB3) (PlasmoDB ID: PF3D7           transmembrane adhesins invasion make 0507200 MEROPS identification number: S08.122)             attractive drug targets. Liver stages, clinically silent, P. falciparum subtilase. PfSUB3 studied    potential targets drug vaccine intervention member P. falciparum subtilases. highly expressed   low abundance distinct metabolism. Study late asexual blood stages [31]. length PfSUB3 gene    proteases expressed liver stages exciting area encodes 88 kDa protein, 25 kDa C-terminal region           research. schematic diagram role P. falciparum serine shown possess serine protease activity       proteases asexual blood stages liver stages shown [37]. Yeast hybrid screening revealed parasite profilin   Figure 1.
(PfPRF), cytoskeletal proinflammatory molecule,           Extensive biochemical structural characterization interacting partner PfSUB3. PfPRF induce          molecules high throughput screening small secretion proinflammatory cytokines 12 TNF-         molecules inhibitors lead way development
ð?›¼ mouse bone marrow-derived dendritic cells. PfSUB3          novel drugs directed proteases.  showed proteolytic activity PfPRF vitro assays           peptidomimetic inhibitors based inhibitory region caused cleavage PfPRF multiple fragments           prodomains developed.
Interdisciplinary Perspectives Infectious Diseases                                                                                          5

                                                                           [2]  â€œWorld malaria report,â€? 2013.
                                                      Subtilisins      [3] J. F. Trape, F. Legros, P. Ndiaye et al., â€œChloroquine-resistant
                                                    rhomboid proteases         Plasmodium falciparum malaria Senegal,â€? Transactions                                                                                Royal Society Tropical Medicine Hygiene, vol. 83,  6, p.
                                                                               761, 1989.
                                  RBC                                      [4] J. R. Zucker, T. K. Ruebush II, C. Obonyo, J. Otieno, C. C.
                                                                               Campbell,  mortality consequences continued use                                                                                chloroquine Africa: experience Siaya, Western Kenya,â€?             Ring               Merozoites                Subtilisins           American Journal Tropical Medicine Hygiene, vol. 68, 
                                                                               4, pp. 386â€“390, 2003.
                                                                           [5] C. H. Sibley, J. E. Hyde, P. F. G. Sims et al., â€œPyrimethamine-
                                                                               sulfadoxine resistance Plasmodium falciparum: â€?
                                                                               Trends Parasitology, vol. 17,  12, pp. 582â€“588, 2001.
                                                                           [6] C. Wongsrichanalai,  L. Pickard, W. H. Wernsdorfer, S.
                                            Schizont                           R. Meshnick, â€œEpidemiology drug-resistant malaria,â€? Lancet
              Trophozoite
                                                                               Infectious Diseases, vol. 2,  4, pp. 209â€“218, 2002.
                                                                         [7] F. Ter Kuile, N. J. White, P. Holloway, G. Pasvol, S. Krishna,
                                       Sporozoite                              â€œPlasmodium falciparum: vitro studies pharmacody-
                                                                               namic properties drugs used treatment severe
                                       (Rhomboid protease                      malaria,â€? Experimental Parasitology, vol. 76,  1, pp. 85â€“95,
                                        activity)                              1993.
              Liver                                                        [8] N. J. White, â€œQinghaosu (artemisinin): price success,â€?
                                                                               Science, vol. 320,  5874, pp. 330â€“334, 2008.
                                       Infected hepatocyte                 [9] W. Ittarat,  L. Pickard, P. Rattanasinganchan et al., â€œRecrude-
      Liver stage                                                              scence artesunate-treated patients falciparum malaria
       schizont                                                                dependent parasite burden parasite factors,â€?                                                                                American Journal Tropical Medicine Hygiene, vol. 68, 
          (SUB1                                                                2, pp. 147â€“152, 2003.
          activity)
                                            (SUB1                        [10] M.  Travassos M. K. Laufer, â€œResistance antimalarial
                                            activity)
                                                                               drugs: molecular, pharmacologic, clinical considerations,â€?
                                                Release liver stage
                                                                               Pediatric Research, vol. 65,  5, pp. 64Râ€“70R, 2009.
                                                merozoites                [11]  M. Dondorp, F. Nosten, P. Yi et al., â€œArtemisinin resistance
                                                                               Plasmodium falciparum malaria,â€? New England Journal                                  (b)                                           Medicine, vol. 361,  5, pp. 455â€“467, 2009.
Figure 1: Role serine proteases asexual blood stages         [12] T. J. C. Anderson, S. Nair, S. Nkhorna et al., â€œHigh heritability
liver stages Plasmodium falciparum (b). Subtilisin-like proteases           malaria parasite clearance rate indicates genetic basis essential merozoite invasion egress blood stages, liver         artemisinin resistance western Cambodia,â€? Journal stage schizont development subsequent liver stage merozoite                Infectious Diseases, vol. 201,  9, pp. 1326â€“1330, 2010.
egress. Rhomboid protease activities supposed involved       [13]  â€œGlobal report antimalarial drug efficacy drug
invasion RBC liver.                                                     resistance: 2000â€“2010,â€? 2010.
                                                                         [14]  Guidelines Treatment Malaria, 2nd edition,
                                                                               2010.
Conflict Interests                                                    [15] B. Turk, â€œTargeting proteases: successes, failures future
                                                                               prospects,â€? Nature Reviews Drug Discovery, vol. 5,  9, pp. 785â€“ author declares conflict interests                     799, 2006.
regarding publication paper.                                 [16] J. H. McKerrow, C. Caffrey, B. Kelly, P. Loke, M. Sajid,
                                                                               â€œProteases parasitic diseases,â€? Annual Review Pathology,
                                                                               vol. 1, pp. 497â€“536, 2006.
Acknowledgments
                                                                         [17] M. Drag G. S. Salvesen, â€œEmerging principles protease-
Data sources PlasmoDB Version 10 gratefully                            based drug discovery,â€? Nature Reviews Drug Discovery, vol. 9,
acknowledged. author thankful Professor Athar                         9, pp. 690â€“701, 2010.
Chishti, Tufts University, USA, proofreading paper.              [18] C. Flexner, G. Bate, P. Kirkpatrick, â€œTipranavir,â€? Nature
                                                                               Reviews Drug Discovery, vol. 4,  12, pp. 955â€“956, 2005.
                                                                         [19]  Melnikova, â€œHepatitis C therapies,â€? Nature Reviews Drug
References                                                                     Discovery, vol. 7,  10, pp. 799â€“800, 2008.
[1] J. G. Breman,  ears hippopotamus: manifestations,         [20] C. G. Smith J. R. Vane,  discovery captopril,â€? FASEB
    determinants, estimates malaria burden,â€? Amer-              Journal, vol. 17,  8, pp. 788â€“789, 2003.
    ican Journal Tropical Medicine Hygiene, vol. 64,  1-2,     [21]  Melnikova,  anticoagulants market,â€? Nature Reviews
    pp. 1â€“11, 2001.                                                            Drug Discovery, vol. 8,  5, pp. 353â€“354, 2009.
6                                                                                       Interdisciplinary Perspectives Infectious Diseases

[22] N. Alkhouri N. N. Zein, â€œProtease inhibitors: silver bullets         [40] M. J. Blackman, H. Fujioka, W. H. L. Stafford et al.,  subtilisin-
      chronic hepatitis C infection?â€? Cleveland Clinic Journal               like protein secretory organelles Plasmodium falciparum
      Medicine, vol. 79,  3, pp. 213â€“222, 2012.                                  merozoites,â€? Journal Biological Chemistry, vol. 273,  36, pp.
[23]  J. P. Docherty, T. Crabbe, J. P. Oâ€™Connell, C. R. Groom,                23398â€“23409, 1998.
      â€œProteases drug targets,â€? Biochemical Society Symposium,           [41] C. Withers-Martinez, J. W. Saldanha, B. Ely, F. Hackett, T.
      70, pp. 147â€“161, 2003.                                                        Oâ€™Connor, M. J. Blackman, â€œExpression recombinant
[24] P. J. Rosenthal, â€œHydrolysis erythrocyte proteins proteases              Plasmodium falciparum subtilisin-like protease-1 insect cells.
      malaria parasites,â€? Current Opinion Hematology, vol. 9,              Characterization, comparison parasite protease,       2, pp. 140â€“145, 2002.                                                         homology modeling,â€? Journal Biological Chemistry, vol. 277,
                                                                                     33, pp. 29698â€“29709, 2002.
[25] M. J. Blackman, â€œProteases involved erythrocyte invasion       malaria parasite: function potential chemotherapeu-          [42] L. Jean, F. Hackett, S. R. Martin, M. J. Blackman, â€œFunc-
      tic targets,â€? Current Drug Targets, vol. 1,  1, pp. 59â€“83, 2000.           tional characterization propeptide Plasmodium falci-
                                                                                    parum subtilisin-like protease-1,â€? Journal Biological Chem-
[26] S. Yeoh, R.  Oâ€™Donnell, K. Koussis et al., â€œSubcellular dis-
                                                                                    istry, vol. 278,  31, pp. 28572â€“28579, 2003.
      charge serine protease mediates release invasive malaria
      parasites host erythrocytes,â€? Cell, vol. 131,  6, pp. 1072â€“     [43] Y. Li,  Hu, F. Jordan, M. Inouye, â€œFunctional analysis       1083, 2007.                                                                   propeptide subtilisin E intramolecular chaperone                                                                                     protein folding. Refolding inhibitory abilities propeptide
[27] S. Arastu-Kapur, E. L. Ponder, U. P. FonoviÂ´c et al., â€œIdentification
                                                                                    mutants,â€? Journal Biological Chemistry, vol. 270,  42, pp.
      proteases regulate erythrocyte rupture malaria
                                                                                    25127â€“25132, 1995.
      parasite Plasmodium falciparum,â€? Nature Chemical Biology, vol.
      4,  3, pp. 203â€“213, 2008.                                            [44] H.-W. Huang, W.-C. Chen, C.-Y. Wu et al., â€œKinetic studies
                                                                                    inhibitory effects propeptides subtilisin BPNâ€™ [28] E. Di Cera, â€œSerine proteases,â€? IUBMB Life, vol. 61,  5, pp.
                                                                                    carlsberg bacterial serine proteases,â€? Protein Engineering, vol.
      510â€“515, 2009.
                                                                                    10,  10, pp. 1227â€“1233, 1997.
[29] R. J. Siezen J.  M. Leunissen, â€œSubtilases: superfamily
                                                                              [45]  Boudreault, D. Gauthier, C. Lazure, â€œProprotein 
      subtilisin-like serine proteases,â€? Protein Science, vol. 6,  3,
                                                                                    vertase PC1/3-related peptides potent slow tight-binding
      pp. 501â€“523, 1997.
                                                                                    inhibitors murine PC1/3 Hfurin,â€? Journal Biological
[30]  Bozdech, M. Llin  B. L. Pulliam, E. D. Wong, J. Zhu,                     Chemistry, vol. 273,  47, pp. 31574â€“31580, 1998.
      J. L. DeRisi,  transcriptome intraerythrocytic
                                                                              [46] Y. Yabuta, H. Takagi, M. Inouye, U. Shinde, â€œFolding
      developmental cycle Plasmodium falciparum,â€? PLoS Biology,
                                                                                    pathway mediated intramolecular chaperone: propeptide
      vol. 1,  1, article E5, 2003.
                                                                                    release modulates activation precision pro-subtilisin,â€? Journal
 [31] K. G. le Roch, Y. Zhou, P. L. Blair et al., â€œDiscovery gene                Biological Chemistry, vol. 276,  48, pp. 44427â€“44434, 2001.
      function expression profiling malaria parasite life
                                                                              [47] M. Fug`ere, P. C. Limperis, V. Beaulieu-Audy et al., â€œInhibitory
      cycle,â€? Science, vol. 301,  5639, pp. 1503â€“1508, 2003.
                                                                                    potency specificity subtilase-like pro-protein convertase
[32] M. Llin   Bozdech, E. D. Wong,  T. Adai, J. L. DeRisi,              (SPC) prodomains,â€? Journal Biological Chemistry, vol. 277, 
      â€œComparative genome transcriptome analysis                     10, pp. 7648â€“7656, 2002.
      Plasmodium falciparum strains,â€? Nucleic Acids Research, vol. 34,
                                                                              [48] M. J. Gardner, H. Tettelin, D. J. Carucci et al., â€œChromosome
       4, pp. 1166â€“1173, 2006.
                                                                                    2 sequence human malaria parasite Plasmodium falci-
[33] M. J. Pallen B. W. Wren,  HtrA family serine                        parum,â€? Science, vol. 282,  5391, pp. 1126â€“1132, 1998.
      proteases,â€? Molecular Microbiology, vol. 26,  2, pp. 209â€“221,
                                                                              [49] E. Pizzi C. Frontali, â€œDivergence noncoding sequences
      1997.
                                                                                    insertions encoding nonglobular domains genomic
[34] C. P. Ponting, â€œEvidence PDZ domains bacteria, yeast,               region conserved plasmodia,â€? Journal Molecular
      plants,â€? Protein Science, vol. 6,  2, pp. 464â€“468, 1997.                   Evolution, vol. 50,  5, pp. 474â€“480, 2000.
[35] N. D. Rawlings, E. Oâ€™Brien,  J. Barrett, â€œMEROPS:              [50] L. Jean, C. Withers-Martinez, F. Hackett, M. J. Blackman,
      protease database,â€? Nucleic Acids Research, vol. 30,  1, pp.               â€œUnique insertions Plasmodium falciparum subtilisin-
      343â€“346, 2002.                                                                like protease-1 crucial enzyme maturation activity,â€?
[36] P. K. Harris, S. Yeoh,  R. Dluzewski et al., â€œMolecular                      Molecular Biochemical Parasitology, vol. 144,  2, pp. 187â€“
      identification malaria merozoite surface sheddase,â€? PLoS                 197, 2005.
      Pathogens, vol. 1,  3, article e29, pp. 0241â€“0251, 2005.              [51] S. Gemma, S. Giovani, M. Brindisi et al., â€œQuinolylhydrazones
[37]  Alam, R. K. Bhatnagar, V. S. Chauhan, â€œExpression                   novel inhibitors Plasmodium falciparum serine protease
      characterization catalytic domain Plasmodium falciparum                 PfSUB1,â€? Bioorganic & Medicinal Chemistry Letters, vol. 22, 
      subtilisin-like protease 3,â€? Molecular Biochemical Parasitol-             16, pp. 5317â€“5321, 2012.
      ogy, vol. 183,  1, pp. 84â€“89, 2012.                                  [52]  Ruecker, M. Shea, F. Hackett, C. Suarez, E. M.  Hirst,
[38]  Alam, R. K. Bhatnagar, U. Relan, P. Mukherjee, V.                       K. Milutinovic, â€œProteolytic activation essential
      S. Chauhan, â€œProteolytic activity Plasmodium falciparum                    parasitophorous vacuole cysteine protease SERA6 accompanies
      subtilisin-like protease 3 parasite profilin, multifunctional            malaria parasite egress host erythrocyte,â€? Journal       protein,â€? Molecular Biochemical Parasitology, vol. 191,  2,            Biological Chemistry, vol. 287,  45, pp. 37949â€“37963, 2012.
      pp. 58â€“62, 2013.                                                        [53] M. J. Blackman, H.-G. Heidrich, S. Donachie, J. S. McBride,
[39] M. Sajid, C. Withers-Martinez, M. J. Blackman, â€œMatu-                        Holder,  single fragment malaria merozoite
      ration specificity Plasmodium falciparum subtilisin-like               surface protein remains parasite red cell invasion
      protease-1, malaria merozoite subtilisin-like serine protease,â€?             target invasion-inhibiting antibodies,â€? Journal       Journal Biological Chemistry, vol. 275,  1, pp. 631â€“641, 2000.          Experimental Medicine, vol. 172,  1, pp. 379â€“382, 1990.
Interdisciplinary Perspectives Infectious Diseases                                                                                              7

[54] V. K. Goel, X. Li, H. Chen, S.-C. Liu,  H. Chishti, S. S.         [68] F. Hackett, M. Sajid, C. Withers-Martinez, M. Grainger,       Oh, â€œBand 3 host receptor binding merozoite surface protein            M. J. Blackman, â€œPfSUB-2: second subtilisin-like protein       1 Plasmodium falciparum invasio